Concepts (80)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antiviral Agents | 2 | 2000 | 510 | 0.260 |
Why?
|
| Hepatitis B Vaccines | 2 | 2001 | 13 | 0.250 |
Why?
|
| Vaccination | 2 | 2001 | 254 | 0.210 |
Why?
|
| Nurseries, Hospital | 1 | 2001 | 2 | 0.200 |
Why?
|
| Guideline Adherence | 2 | 2001 | 223 | 0.180 |
Why?
|
| Herpesvirus 2, Human | 1 | 2000 | 45 | 0.180 |
Why?
|
| Acyclovir | 1 | 2000 | 107 | 0.180 |
Why?
|
| Chickenpox | 1 | 1998 | 39 | 0.160 |
Why?
|
| Cytomegalovirus Infections | 1 | 1998 | 144 | 0.150 |
Why?
|
| Practice Guidelines as Topic | 2 | 2001 | 1034 | 0.150 |
Why?
|
| Herpes Simplex | 1 | 1998 | 202 | 0.150 |
Why?
|
| Infant, Newborn | 3 | 2001 | 2378 | 0.070 |
Why?
|
| Tuberculosis, Central Nervous System | 1 | 2003 | 2 | 0.060 |
Why?
|
| Otitis Media, Suppurative | 1 | 2003 | 4 | 0.060 |
Why?
|
| Mastoiditis | 1 | 2003 | 4 | 0.060 |
Why?
|
| Tuberculosis, Miliary | 1 | 2003 | 4 | 0.060 |
Why?
|
| Genes, Viral | 1 | 2002 | 116 | 0.050 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2002 | 64 | 0.050 |
Why?
|
| Thimerosal | 1 | 2001 | 6 | 0.050 |
Why?
|
| Preservatives, Pharmaceutical | 1 | 2001 | 10 | 0.050 |
Why?
|
| HIV-1 | 1 | 2002 | 163 | 0.050 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2003 | 186 | 0.050 |
Why?
|
| Thymidine Kinase | 1 | 2000 | 30 | 0.050 |
Why?
|
| Drug Resistance, Microbial | 1 | 2000 | 72 | 0.050 |
Why?
|
| Vancomycin | 1 | 2000 | 72 | 0.050 |
Why?
|
| Vero Cells | 1 | 2000 | 100 | 0.050 |
Why?
|
| Public Housing | 1 | 1999 | 7 | 0.050 |
Why?
|
| Mutation | 2 | 2002 | 3967 | 0.050 |
Why?
|
| Anti-HIV Agents | 1 | 2002 | 149 | 0.050 |
Why?
|
| Illinois | 1 | 2001 | 462 | 0.040 |
Why?
|
| Fatal Outcome | 1 | 2000 | 293 | 0.040 |
Why?
|
| Cricetinae | 1 | 2000 | 560 | 0.040 |
Why?
|
| Virus Replication | 1 | 2000 | 319 | 0.040 |
Why?
|
| Immunocompetence | 1 | 1998 | 27 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 1 | 2000 | 1041 | 0.040 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2000 | 508 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 1 | 2000 | 746 | 0.030 |
Why?
|
| Child, Preschool | 4 | 2003 | 3611 | 0.030 |
Why?
|
| HIV Infections | 1 | 2002 | 772 | 0.030 |
Why?
|
| Humans | 7 | 2003 | 86601 | 0.020 |
Why?
|
| Urban Population | 2 | 2002 | 213 | 0.020 |
Why?
|
| Mice | 1 | 2000 | 11352 | 0.020 |
Why?
|
| Follow-Up Studies | 2 | 2003 | 3636 | 0.020 |
Why?
|
| Risk Assessment | 2 | 2003 | 2261 | 0.020 |
Why?
|
| Infant | 2 | 2000 | 3045 | 0.010 |
Why?
|
| Female | 3 | 2003 | 44507 | 0.010 |
Why?
|
| Developed Countries | 1 | 2003 | 24 | 0.010 |
Why?
|
| Antitubercular Agents | 1 | 2003 | 52 | 0.010 |
Why?
|
| Rare Diseases | 1 | 2003 | 59 | 0.010 |
Why?
|
| Sampling Studies | 1 | 2002 | 70 | 0.010 |
Why?
|
| Viral Load | 1 | 2002 | 148 | 0.010 |
Why?
|
| Treatment Failure | 1 | 2002 | 285 | 0.010 |
Why?
|
| Probability | 1 | 2002 | 355 | 0.010 |
Why?
|
| Male | 2 | 2002 | 40956 | 0.010 |
Why?
|
| Adult | 1 | 2000 | 25640 | 0.010 |
Why?
|
| Animals | 1 | 2000 | 26581 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2002 | 916 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2002 | 912 | 0.010 |
Why?
|
| Poliovirus Vaccine, Inactivated | 1 | 1999 | 2 | 0.010 |
Why?
|
| Diphtheria-Tetanus-Pertussis Vaccine | 1 | 1999 | 2 | 0.010 |
Why?
|
| Child | 2 | 2002 | 6926 | 0.010 |
Why?
|
| Measles Vaccine | 1 | 1999 | 7 | 0.010 |
Why?
|
| Immunization Schedule | 1 | 1999 | 21 | 0.010 |
Why?
|
| Treatment Outcome | 2 | 2003 | 7988 | 0.010 |
Why?
|
| Immunization Programs | 1 | 1999 | 23 | 0.010 |
Why?
|
| Hospitals, Pediatric | 1 | 2000 | 106 | 0.010 |
Why?
|
| Hepatitis B | 1 | 1999 | 74 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2003 | 1685 | 0.010 |
Why?
|
| Data Collection | 1 | 2000 | 372 | 0.010 |
Why?
|
| Adolescent | 2 | 2002 | 8979 | 0.010 |
Why?
|
| Survival Rate | 1 | 2002 | 1860 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2002 | 1961 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2002 | 1990 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2003 | 1801 | 0.010 |
Why?
|
| Genotype | 1 | 2002 | 1850 | 0.010 |
Why?
|
| Chicago | 1 | 1999 | 1379 | 0.010 |
Why?
|
| Physicians | 1 | 2000 | 673 | 0.010 |
Why?
|
| Internship and Residency | 1 | 2000 | 1004 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2002 | 8475 | 0.010 |
Why?
|
| United States | 1 | 2000 | 6665 | 0.000 |
Why?
|